Quick Answer
SUTRO BIOPHARMA, INC. reported Long-Term Debt of $0.00 for fiscal year 2023.
SUTRO BIOPHARMA, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2023 | $0.00 | -100.0% |
| 2022 | $3.77M | -76.0% |
| 2021 | $15.74M | -35.9% |
| 2020 | $24.55M | +176.5% |
| 2019 | $8.88M | -11.2% |
| 2018 | $10.00M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2022 | $3.77M | -76.0% | -44.4% |
| September 30, 2022 | $6.78M | -63.8% | -30.6% |
| June 30, 2022 | $9.78M | -54.9% | -23.4% |
| March 31, 2022 | $12.76M | -48.3% | -18.9% |
| December 31, 2021 | $15.74M | -35.9% | -15.9% |
| September 30, 2021 | $18.71M | -23.3% | -13.7% |
| June 30, 2021 | $21.69M | -10.7% | -12.1% |
| March 31, 2021 | $24.68M | +2.2% | +0.6% |
- SUTRO BIOPHARMA, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2018–2023 period, SUTRO BIOPHARMA, INC.’s long-term debt has declined by 100.0% (from $10.00 million to $0.00).
- The most recent figure is from SUTRO BIOPHARMA, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 25, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: